Prescribing at 95 years of age: cross-sectional findings from the Newcastle 85+ study.
Journal
International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
09
03
2022
accepted:
25
06
2022
pubmed:
30
7
2022
medline:
24
8
2022
entrez:
29
7
2022
Statut:
ppublish
Résumé
Previous research has examined prescribing amongst 85-year-olds in English primary care, but less is known about prescribing amongst 95-year-olds in spite of population ageing. We describe the most commonly prescribed medicines in a cohort of 95-year-olds, using 10-year follow-up data from the Newcastle 85+ Study (n = 90). A total of 1040 participants were recruited to the Newcastle 85+ Study through general practices at 85-years of age, and 90 surviving participants were re-contacted and assessed at 95-years of age. Prescribed medications from general practice medical records were examined through cross-tabulations and classified as preventative or for symptom control based on their customary usage. Preventative medications with unclear evidence of benefit such as statins (36.7%), aspirin (21.1%) and bisphosphonates (18.9%) were frequently prescribed. Future research in a larger clinical dataset could investigate this preliminary trend, which suggests that benefit/risk information for preventive medication, and evidence for deprescribing, is needed in the very old.
Sections du résumé
BACKGROUND
BACKGROUND
Previous research has examined prescribing amongst 85-year-olds in English primary care, but less is known about prescribing amongst 95-year-olds in spite of population ageing.
AIM
OBJECTIVE
We describe the most commonly prescribed medicines in a cohort of 95-year-olds, using 10-year follow-up data from the Newcastle 85+ Study (n = 90).
METHOD
METHODS
A total of 1040 participants were recruited to the Newcastle 85+ Study through general practices at 85-years of age, and 90 surviving participants were re-contacted and assessed at 95-years of age. Prescribed medications from general practice medical records were examined through cross-tabulations and classified as preventative or for symptom control based on their customary usage.
RESULTS
RESULTS
Preventative medications with unclear evidence of benefit such as statins (36.7%), aspirin (21.1%) and bisphosphonates (18.9%) were frequently prescribed.
CONCLUSIONS
CONCLUSIONS
Future research in a larger clinical dataset could investigate this preliminary trend, which suggests that benefit/risk information for preventive medication, and evidence for deprescribing, is needed in the very old.
Identifiants
pubmed: 35906504
doi: 10.1007/s11096-022-01454-z
pii: 10.1007/s11096-022-01454-z
pmc: PMC9362142
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1072-1077Subventions
Organisme : NIHR School for Primary Care Research
ID : SPCR-2014-10043
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Tomassini C. The demographic characteristics of the oldest old in the United Kingdom. Popul Trends. 2005;120:15–22.
Davies LE, Kingston A, Todd A, et al. Characterising polypharmacy in the very old: findings from the Newcastle 85+ Study. PLoS ONE. 2021;16(1):e0245648.
doi: 10.1371/journal.pone.0245648
Tsoi CS, Chow JY, Choi KS, et al. Medical characteristics of the oldest old: retrospective chart review of patients aged 85+ in an academic primary care centre. BMC Res Notes. 2014;7:340.
doi: 10.1186/1756-0500-7-340
Wågert PvH, Gustavsson JMC, Lundin-Olsson L, et al. Health status in the oldest old. Age and sex differences in the Umeå 85+ Study. Aging Clin Exp Res. 2006;18(2):116–26.
doi: 10.1007/BF03327426
Onder G, Marengoni A, Russo P, et al. Advanced age and medication prescription: more years, less medications? A nationwide report from the Italian medicines agency. J Am Med Dir Assoc. 2016;17(2):168–72.
doi: 10.1016/j.jamda.2015.08.009
Nosraty L, Sarkeala T, Hervonen A, et al. Is there successful aging for nonagenarians? The vitality 90+ study. J Aging Res. 2012;2012:868797
doi: 10.1155/2012/868797
Lee DR, Kawas CH, Gibbs L, et al. Prevalence of frailty and factors associated with frailty in individuals aged 90 and older: the 90 + study. J Am Geriatr Soc. 2016;64(11):2257–62.
doi: 10.1111/jgs.14317
Corrada MM, Brookmeyer R, Paganini-Hill A, et al. Dementia incidence continues to increase with age in the oldest old: the 90 + study. Ann Neurol. 2010;67(1):114–21.
doi: 10.1002/ana.21915
Berlau DJ, Corrada MM, Kawas C. The prevalence of disability in the oldest-old is high and continues to increase with age: findings from The 90+ Study. Int J Geriatr Psychiatry. 2009;24(11):1217–25.
doi: 10.1002/gps.2248
Holmes HM. Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther. 2009;85(1):103–7.
doi: 10.1038/clpt.2008.211
Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605–9.
doi: 10.1001/archinte.166.6.605
Collerton J, Davies K, Jagger C, et al. Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. BMJ. 2009;339:b4904.
doi: 10.1136/bmj.b4904
Davies K, Collerton JC, Jagger C, et al. Engaging the oldest old in research: lessons from the Newcastle 85+ study. BMC Geriatr. 2010;10(1):64.
doi: 10.1186/1471-2318-10-64
Collerton J, Barrass K, Bond J, et al. The Newcastle 85+ study: biological, clinical and psychosocial factors associated with healthy ageing: study protocol. BMC Geriatr. 2007;7:14.
doi: 10.1186/1471-2318-7-14
Mendonça N, Kingston A, Yadegarfar M, et al. Transitions between frailty states in the very old: the influence of socioeconomic status and multi-morbidity in the Newcastle 85+ cohort study. Age Ageing. 2020;49(6):974–81.
doi: 10.1093/ageing/afaa054
Molloy D, Standish T. A guide to the standardized mini-mental state examination. Int Psychogeriatr. 1997;9:87–94.
doi: 10.1017/S1041610297004754
Royal College of Physicians Intercollegiate Stroke Working Party. National clinical guideline for stroke, 2016.
Gulliford M, Ravindrarajah R, Hamada S, et al. Inception and deprescribing of statins in people aged over 80 years: cohort study. Age Age. 2017;46(6):1001–5.
doi: 10.1093/ageing/afx100
Li L, Geraghty OC, Mehta Z, et al. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390(10093):490–9.
doi: 10.1016/S0140-6736(17)30770-5
National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management, 2016.
Maddison AR, Fisher J, Johnston G. Preventive medication use among persons with limited life expectancy. Prog Palliat Care. 2011;19(1):15–21.
doi: 10.1179/174329111X576698
Anderson K, Stowasser D, Freeman C, et al. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544.
doi: 10.1136/bmjopen-2014-006544
Bain KT, Holmes HM, Beers MH, et al. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc. 2008;56(10):1946–52.
doi: 10.1111/j.1532-5415.2008.01916.x
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22(8):983–8.
doi: 10.1161/01.STR.22.8.983
Guthrie B, McCowan C, Davey P, et al. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ. 2011;342:d3514.
doi: 10.1136/bmj.d3514
Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15.
doi: 10.1136/bmj.329.7456.15
Cherubini A, Corsonello A, Lattanzio F. Underprescription of beneficial medicines in older people. Drugs Aging. 2012;29(6):463–75.
doi: 10.2165/11631750-000000000-00000
Jones NR, Hobbs FDR, Taylor CJ. Underuse of anticoagulation therapy for atrial fibrillation: are we failing our patients? Can Fam Phys. 2017;63(12):943–4.
Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science. 1974;185(4157):1124–31.
doi: 10.1126/science.185.4157.1124
Johnell K. The controversies surrounding polypharmacy in old age—where are we? Expert Rev Clin Pharmacol. 2018;11(9):825–7
doi: 10.1080/17512433.2018.1510313
Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ (Clin Res Ed). 2008;336(7634):2–3.
doi: 10.1136/bmj.39406.449456.BE
Maidment I, Lawson S, Wong G, et al. Towards an understanding of the burdens of medication management affecting older people: the MEMORABLE realist synthesis. BMC Geriatr. 2020;20(1):183.
doi: 10.1186/s12877-020-01568-x
Alldred DP. Deprescribing: a brave new word? Int J Pharm Pract. 2014;22(1):2–3.
doi: 10.1111/ijpp.12093
Reeve E, Thompson W, Farrell B. Deprescribing. A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med. 2017;38:3–11.
doi: 10.1016/j.ejim.2016.12.021
Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175(5):691–700.
doi: 10.1001/jamainternmed.2015.0289
Jagger C, Collerton JC, Davies K, et al. Capability and dependency in the Newcastle 85+ cohort study. Projections of future care needs. BMC Geriatr. 2011;11(1):21.
doi: 10.1186/1471-2318-11-21